Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer/Sanofi speculation

Executive Summary

Rumors are cropping up regarding potential acquisition of Sanofi-Aventis, or at least a stake in the company, by Pfizer - which has a hefty amount of cash on hand and a pipeline to fill. Sanofi has been the subject of various acquisition rumors, including reports that the company was considering acquiring Plavix (clopidogrel) and Avapro (irbesartan) marketing partner Bristol-Myers Squibb (1"The Pink Sheet" Aug. 14, 2006, p. 3). Merging might not be in the best interest of either company, as both firms' biggest products lose exclusivity in the same timeframe: Pfizer's Lipitor (atorvastatin) in 2010 and Plavix in 2011. Pfizer's recently announced R&D strategy includes working to secure external opportunities in targeted areas through acquisitions, licensing and development, joint venture and alliances and other collaborative agreements (2"The Pink Sheet" Oct. 8, 2007, p. 3)...

You may also be interested in...

Pfizer Promotes Global R&D VP Mackay To Head Unit, Opens Biotech Center

Pfizer, as part of its ongoing efforts to reinvent its R&D model, is aiming to accelerate product development under a new leadership team and establish a significant presence in biotechnology with a new facility devoted to "bioinnovation.

Bristol May Be An Acquisition Target Following Entry Of Plavix Generics

The entry of generic competition for Bristol-Myers Squibb/Sanofi-Aventis' blockbuster antithrombotic Plavix could make Bristol an acquisition target

HRA Pharma UK Sponsors World Record Attempt

Perrigo subsidiary HRA Pharma's Compeed foot-care brand is sponsoring the UK's Wendy Searle in her attempt to break the world record for fastest woman to ski solo and unassisted from the Antarctic coast to the South Pole this winter.

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts